ALFA Finder| Revenue growth | 15% YoY revenue growth guided consistently for coming years. |
|---|---|
| Margins | Targeting 0.5% to 1% annual gross margin improvement. |
| Demand visibility | Strong in infertility and botulinum toxin (23% market share). |
| Management confidence | High; citing Indore breakeven and successful working capital reset. |
Growth
Q4 revenue grew 23% YoY; PAT more than doubled. FY26 revenue reached ₹940.5cr with 16.26% EBITDA margin.
Outlook
Guidance of 15% annual revenue growth; EBITDA margins targeted at 18% for FY27 and 20%+ by 2030.
Risks
Transitioning Critical Care distribution cost ₹22cr in revenue; high R&D spend (8-10% of revenue) impacts short-term PAT.
Earnings Call filed with BSE, NSE: GUFICBIO. Summary written with AI assistance from the document.
Gufic BioSciences Ltd: key numbers
- Share price
- ₹478.55
- Market cap
- ₹4,799 Cr
- Revenue (annual)
- ₹944.0 Cr
- Net profit (annual)
- ₹64.21 Cr
- P/E (TTM)
- 65.3×Sector 43.8×
- Promoter holding
- 72.50%+0.00% QoQ
- FII holding
- 0.44%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gufic BioSciences Ltd
All →Gufic BioSciences Board Meeting Date
Gufic Biosciences gives notice of a board meeting on 14 November 2026 to consider unaudited standalone and consolidated quarterly results. The filing carries no financial figures or business decision.
Gufic BioSciences Legal & Regulatory
Gufic Biosciences' tax dispute moved after the ITAT remanded matters to the Assessing Officer. The residual Rs. 11.76 lakh demand will be redetermined in fresh assessment.
- Value
- ₹0.12 Cr
Gufic BioSciences Legal & Regulatory
Gufic Biosciences disclosed an ITAT Mumbai order for AY 2023-24 that set aside the CIT(A) findings and restored the matter to the Assessing Officer. No demand arises from the order, and the tax liability will be determined after fresh assessment.
Gufic BioSciences Business Update
Gufic Biosciences reported a USFDA pre-approval inspection at its Indore facility, concluding October 23, 2026. The inspection produced three Form 483 observations, now being addressed.
Gufic BioSciences Other Announcement
Gufic Biosciences Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Gufic BioSciences Legal & Regulatory
Gufic Biosciences received a favorable appellate order from the Income Tax Commissioner. This order deletes an income tax demand of Rs. 4.33 Crore.
- Value
- ₹4.33 Cr